TATX 03
Alternative Names: PolyTope® TATX-03 antibody cocktail therapy; TATX-03; TATX-03 PolyTope™ Therapy; TATX-03a; TATX-03bLatest Information Update: 28 Mar 2025
At a glance
- Originator Talem Therapeutics
- Class Anti-inflammatories; Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for preclinical development in COVID-2019-infections in USA (Parenteral)
- 28 Mar 2025 No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in USA (Parenteral)
- 04 Dec 2023 TATX 03 is available for licensing as of 04 Dec 2023. https://www.talemtherapeutics.com/antibody-therapeutics-pipeline